Items Tagged ‘perjeta’

August 30th, 2017

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with Herceptin and Perjeta and have disease progression after ado-trastuzumab (T-DM1). Breakthrough Therapy designation is designed to […]

View full entry

Tags: ado-trastuzumab, Breast Cancer, DS-8201, HER2-positive, herceptin, locally advanced, Metastatic Breast Cancer, News, perjeta, Precision Cancer Medicine, T-DM1


October 9th, 2014

Impressive Survival Gains with New First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By

According to recent findings, the combination of targeted agents Herceptin® (trastuzumab) and Perjeta® (perjeta) significantly improves survival for patients with HER2-positive metastatic breast cancer when added to chemotherapy. This data was presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] HER2 is a protein involved in normal cell […]

View full entry

Tags: Breast Cancer, HER2, herceptin, Metastatic Breast Cancer, News, perjeta, Recurrent Breast Cancer